XXXX outcomes: Predictors of early death.

@entity43 @entity1
OBJECTIVE: To describe the outcomes and mortality in advanced @entity43 @entity1 in a population-based cohort in the 90days after diagnosis. METHODS: Using the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database, we identified a cohort of @entity1 with @entity43 diagnosed between 1995 and 2007. A   (2) test was used to assess demographic and clinical factors. Kaplan-Meier curves and Cox proportional hazards models were used to assess factors associated with variation in survival. RESULTS: Of the 9491 @entity1 with stage III/IV @entity43 identified from the SEER/Medicare system, 4131 (43.6%) @entity1 died in the first year after diagnosis. Of these, 2472 (26.0%) @entity1 died in the first 90days after diagnosis. Over the study period, the number of @entity1 who died in the first 90days after diagnosis slightly increased (p=0.053). Older age (>75years of age), increased comorbidity, stage IV disease, lack of a visit with a gynecologic oncologist, and surgery were associated with an increase in 90-day mortality. Chemotherapy was associated with a reduction in 90-day mortality. CONCLUSIONS: Approximately 25% of @entity1 with advanced @entity43 in our study period died within 90days of diagnosis, and more than 40% died within the first year of diagnosis. In addition, a substantial proportion of @entity1 did not receive any treatment. Further research into the characteristics of these @entity1 should be performed to elucidate clinical areas for intervention to either prevent these poor outcomes or allocate appropriate resources to @entity1 with extremely poor prognoses.
